vTv Therapeutics Inc. (VTVT) is a clinical-stage pharmaceutical company that majors in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company trades on the NASDAQ Stock Market under the ticker VTVT. vTv Therapeutics was incorporated in April 2015 and has its headquarters in High Point, North Carolina.
vTv’s drug development program relies on the company’s innovative technology platform, TTP Translational Technology, that leverages comprehensive data sets and next-generation computational tools. This platform allows for the efficient analoging, screening and testing of candidates, shortening the development timelines.
The company’s key drug candidates are azeliragon and TTP399. Azeliragon is an oral antagonist of the Receptor for Advanced Glycation End Products (RAGE) developed for the treatment of Alzheimer's disease. Clinical trials for this drug candidate, unfortunately, failed to demonstrate efficacy in 2018. However, vTv is exploring options to pursue azeliragon’s further development.
TTP399, on the other hand, is a glucokinase activator considered as a potential treatment for type 1 and type 2 diabetes. Results from clinical studies suggest it may provide a new approach to treat diabetes without causing low blood sugar or weight gain, side effects often associated with other treatments.
vTv Therapeutics' business model follows a lean operating structure, partnering with larger pharmaceutical companies to maximize the value of their programs and further their drug candidates. Its commercialization strategy includes securing agreements with strategic partners for further clinical development and commercialization of their drug candidates in different regions.
Despite the setbacks and challenges, vTv continues to channel its efforts on advancing its pipeline of clinical-stage drug candidates. The company is dedicated to addressing significant unmet medical needs and transforming treatment paradigms in neurodegenerative diseases and type 1 diabetes. vTv’s ultimate aim is to contribute to the well-being of patients, delivering innovative drugs that can have a meaningful impact on people's lives.